HuGE Literature Finder
Records
1
-
8
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Oncology 2016 Sep . Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A, Matulonis Ursu |
| DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The New England journal of medicine 2015 Oct 373 (18): 1697-708. Mateo Joaquin, Carreira Suzanne, Sandhu Shahneen, Miranda Susana, Mossop Helen, Perez-Lopez Raquel, Nava Rodrigues Daniel, Robinson Dan, Omlin Aurelius, Tunariu Nina, Boysen Gunther, Porta Nuria, Flohr Penny, Gillman Alexa, Figueiredo Ines, Paulding Claire, Seed George, Jain Suneil, Ralph Christy, Protheroe Andrew, Hussain Syed, Jones Robert, Elliott Tony, McGovern Ursula, Bianchini Diletta, Goodall Jane, Zafeiriou Zafeiris, Williamson Chris T, Ferraldeschi Roberta, Riisnaes Ruth, Ebbs Bernardette, Fowler Gemma, Roda Desamparados, Yuan Wei, Wu Yi-Mi, Cao Xuhong, Brough Rachel, Pemberton Helen, A'Hern Roger, Swain Amanda, Kunju Lakshmi P, Eeles Rosalind, Attard Gerhardt, Lord Christopher J, Ashworth Alan, Rubin Mark A, Knudsen Karen E, Feng Felix Y, Chinnaiyan Arul M, Hall Emma, de Bono Johann |
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
| The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet. Oncology 2011 Sep 12 (9): 852-61. Gelmon Karen A, Tischkowitz Marc, Mackay Helen, Swenerton Kenneth, Robidoux André, Tonkin Katia, Hirte Hal, Huntsman David, Clemons Mark, Gilks Blake, Yerushalmi Rinat, Macpherson Euan, Carmichael James, Oza Am |
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England) 2010 Jul 376 (9737): 235-44. Tutt Andrew, Robson Mark, Garber Judy E, Domchek Susan M, Audeh M William, Weitzel Jeffrey N, Friedlander Michael, Arun Banu, Loman Niklas, Schmutzler Rita K, Wardley Andrew, Mitchell Gillian, Earl Helena, Wickens Mark, Carmichael Jam |
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (London, England) 2010 Jul 376 (9737): 245-51. Audeh M William, Carmichael James, Penson Richard T, Friedlander Michael, Powell Bethan, Bell-McGuinn Katherine M, Scott Clare, Weitzel Jeffrey N, Oaknin Ana, Loman Niklas, Lu Karen, Schmutzler Rita K, Matulonis Ursula, Wickens Mark, Tutt Andr |
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine 2009 Jul 361 (2): 123-34. Fong Peter C, Boss David S, Yap Timothy A, Tutt Andrew, Wu Peijun, Mergui-Roelvink Marja, Mortimer Peter, Swaisland Helen, Lau Alan, O'Connor Mark J, Ashworth Alan, Carmichael James, Kaye Stan B, Schellens Jan H M, de Bono Johann |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 22, 2022
- Content source: